Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis

J Drugs Dermatol. 2019 Mar 1;18(3):297-299.


Recently, clinical data on 8 weeks’ once-daily treatment of localized moderate-to-severe psoriasis with a novel fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion were published.1,2 HP/TAZ lotion was significantly more effective than individual active ingredients or vehicle, based on improvements in Investigator’s Global Assessment (IGA), body surface area (BSA) involvement, and signs and symptoms of psoriasis (erythema, plaque elevation, and scaling) at the target lesion as well as a synergistic benefit over individual active ingredients, and good tolerability.

MeSH terms

  • Administration, Cutaneous
  • Clinical Trials, Phase III as Topic
  • Clobetasol / administration & dosage
  • Clobetasol / analogs & derivatives*
  • Dermatologic Agents / administration & dosage*
  • Drug Administration Schedule
  • Drug Combinations
  • Humans
  • Multicenter Studies as Topic
  • Nicotinic Acids / administration & dosage*
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Severity of Illness Index
  • Skin Cream
  • Treatment Outcome


  • Dermatologic Agents
  • Drug Combinations
  • Nicotinic Acids
  • tazarotene
  • halobetasol
  • Clobetasol